These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 14616979)

  • 1. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.
    Voskaridou E; Terpos E; Spina G; Palermos J; Rahemtulla A; Loutradi A; Loukopoulos D
    Br J Haematol; 2003 Nov; 123(4):730-7. PubMed ID: 14616979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
    Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
    Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
    Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A
    Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
    Terpos E; Viniou N; de la Fuente J; Meletis J; Voskaridou E; Karkantaris C; Vaiopoulos G; Palermos J; Yataganas X; Goldman JM; Rahemtulla A
    Eur J Haematol; 2003 Jan; 70(1):34-42. PubMed ID: 12631257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle.
    Morabito N; Gaudio A; Lasco A; Atteritano M; Pizzoleo MA; Cincotta M; La Rosa M; Guarino R; Meo A; Frisina N
    J Bone Miner Res; 2004 May; 19(5):722-7. PubMed ID: 15068494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
    Mezquita-Raya P; de la Higuera M; García DF; Alonso G; Ruiz-Requena ME; de Dios Luna J; Escobar-Jiménez F; Muñoz-Torres M
    Osteoporos Int; 2005 Nov; 16(11):1368-74. PubMed ID: 15711777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women.
    Zhao HY; Liu JM; Ning G; Zhao YJ; Zhang LZ; Sun LH; Xu MY; Uitterlinden AG; Chen JL
    Osteoporos Int; 2005 Dec; 16(12):1519-24. PubMed ID: 15782282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial.
    Voskaridou E; Anagnostopoulos A; Konstantopoulos K; Stoupa E; Spyropoulou E; Kiamouris C; Terpos E
    Haematologica; 2006 Sep; 91(9):1193-202. PubMed ID: 16956818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density.
    Suzuki K; Kurose T; Takizawa M; Maruyama M; Ushikawa K; Kikuyama M; Sugimoto C; Seino Y; Nagamatsu S; Ishida H
    Diabetes Res Clin Pract; 2005 May; 68(2):117-25. PubMed ID: 15860239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.
    Perifanis V; Vyzantiadis T; Tziomalos K; Vakalopoulou S; Garipidou V; Athanassiou-Metaxa M; Harsoulis F
    Ann Hematol; 2007 Jan; 86(1):23-30. PubMed ID: 17013645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
    Terpos E; Heath DJ; Rahemtulla A; Zervas K; Chantry A; Anagnostopoulos A; Pouli A; Katodritou E; Verrou E; Vervessou EC; Dimopoulos MA; Croucher PI
    Br J Haematol; 2006 Dec; 135(5):688-92. PubMed ID: 17107351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma.
    Terpos E; Politou M; Szydlo R; Nadal E; Avery S; Olavarria E; Kanfer E; Goldman JM; Apperley JF; Rahemtulla A
    Leukemia; 2004 Aug; 18(8):1420-6. PubMed ID: 15215875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis.
    Gonnelli S; Montagnani A; Caffarelli C; Cadirni A; Campagna MS; Franci MB; Lucani B; Gaggiotti E; Nuti R
    J Endocrinol Invest; 2005 Jun; 28(6):534-9. PubMed ID: 16117195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.
    Jung K; Lein M; Ringsdorf M; Roigas J; Schnorr D; Loening SA; Staack A
    J Urol; 2006 Oct; 176(4 Pt 1):1326-31. PubMed ID: 16952623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG).
    Sasaki N; Kusano E; Takahashi H; Ando Y; Yano K; Tsuda E; Asano Y
    J Bone Miner Metab; 2005; 23(1):41-7. PubMed ID: 15616893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75.
    Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang Zh; Sun LH; Xu MY; Chen JL
    Calcif Tissue Int; 2005 Jan; 76(1):1-6. PubMed ID: 15455183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
    Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F
    Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
    Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
    Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.